185 related articles for article (PubMed ID: 26251767)
21. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
22. RANK and RANK ligand expression in primary human osteosarcoma.
Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
[TBL] [Abstract][Full Text] [Related]
23. Giant-cell tumor of bone: treatment options and role of denosumab.
Singh AS; Chawla NS; Chawla SP
Biologics; 2015; 9():69-74. PubMed ID: 26203221
[TBL] [Abstract][Full Text] [Related]
24. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
26. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
28. Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.
Akeda K; Kasai Y; Sakakibara T; Matsumine A; Takegami N; Yamada J; Sudo A
Spine (Phila Pa 1976); 2015 May; 40(10):E601-8. PubMed ID: 25955096
[TBL] [Abstract][Full Text] [Related]
29. Giant-cell tumor of bone, anti-RANKL therapy.
Dufresne A; Derbel O; Cassier P; Vaz G; Decouvelaere AV; Blay JY
Bonekey Rep; 2012 Sep; 1():149. PubMed ID: 24363925
[TBL] [Abstract][Full Text] [Related]
30. Radiological and Histopathological Outcome of Giant Cell Tumor of Femur with Denosumab Treatment: A Case Report.
Menon PD; Krishnakumar R; Jojo A
J Clin Diagn Res; 2016 Dec; 10(12):RD01-RD03. PubMed ID: 28208958
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report.
Marinova VV; Slavchev SA; Patrikov KD; Tsenova PM; Georgiev GP
Folia Med (Plovdiv); 2018 Dec; 60(4):637-640. PubMed ID: 31188771
[TBL] [Abstract][Full Text] [Related]
32. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
33. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
34. Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature.
Nasca V; Frezza AM; Morosi C; Buonomenna C; Parafioriti A; Zappalà G; Bini F; Casali PG; Loppini M; Stacchiotti S
Front Oncol; 2022; 12():953149. PubMed ID: 35928864
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
[TBL] [Abstract][Full Text] [Related]
36. Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.
Borkowska AM; Szumera-Ciećkiewicz A; Szostakowski B; Pieńkowski A; Rutkowski PL
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565419
[TBL] [Abstract][Full Text] [Related]
37. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report.
Yamagishi T; Kawashima H; Ogose A; Sasaki T; Hotta T; Inagawa S; Umezu H; Endo N
Oncol Lett; 2016 Jan; 11(1):243-246. PubMed ID: 26870196
[TBL] [Abstract][Full Text] [Related]
38. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
Mak IW; Evaniew N; Popovic S; Tozer R; Ghert M
J Bone Joint Surg Am; 2014 Aug; 96(15):e127. PubMed ID: 25100780
[TBL] [Abstract][Full Text] [Related]
39. Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review.
Alhumaid I; Abu-Zaid A
Cureus; 2019 Jan; 11(1):e3989. PubMed ID: 30972268
[TBL] [Abstract][Full Text] [Related]
40. Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab.
Mattei TA; Ramos E; Rehman AA; Shaw A; Patel SR; Mendel E
Spine J; 2014 Jul; 14(7):e15-21. PubMed ID: 24534393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
